Emergency Contraception Clinical Trial
— AFTEROfficial title:
AFTER: Application for the Etonogestrel/Ethinyl Estradiol Ring--potential for Emergency Contraception
This study is enrolling healthy women ages 18-39yo who are not pregnant or breastfeeding, and are not using hormonal birth control. Initial screening visit will include a blood draw to assess if the participant has recently ovulated. If hormone test indicates ovulation occurred, participant will start the study 8 days after the start of their next menstrual period. On this study visit, vaginal ultrasound will be performed to look the ovaries for follicles. Vaginal ultrasound is then performed approximately every 2 days until the dominant follicle has grown into the size group assigned. When this occurs the participant will place the NuvaRing®, inside the vagina and blood will be drawn for hormone levels. Participant will then return daily the next 5 days (total of 6 daily visits) for vaginal ultrasound and blood draw to assess for signs of ovulation. After the 7th day the ring is in the vagina, the participant will remove the ring from her vagina at home. After removal, there will be twice weekly clinic visits for ultrasound and blood draw until menstrual bleeding occurs. At this point, participation in the study is complete. Participants are compensated for their time.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | July 1, 2018 |
Est. primary completion date | June 30, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 39 Years |
Eligibility |
Inclusion Criteria: - Healthy, women ages 18 to 39yo with BMI <30 - Regular menstrual cycles with duration between 24-35 days - Completion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater) - Not seeking pregnancy during the study period - Use of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence - Must speak English or Spanish Exclusion Criteria: - Currently pregnant or breastfeeding - Severe pelvic organ prolapse or prolapse to any degree that may prevent retention of the vaginal ring after insertion - Use of oral contraceptive pills, patches, implants or hormonal intrauterine contraception in the month prior to screening - Use of depo medroxyprogesterone within 6 months of screening - Use of medications that interact with contraceptive steroid hormones: anti-epileptic medications, rifampin, rifabutin, fosamprenavir, etc - Medical condition with safety deemed to be category 3 or 4 when using a combined hormonal contraceptive, as determined by the Center for Disease Control Medical Eligibility Criteria: current or past history of breast cancer, severe decompensated cirrhosis, history of deep vein thrombosis or pulmonary embolus, diabetes with nephropathy/retinopathy/neuropathy or other vascular disease diagnosed more than 20 years ago, current symptomatic gallbladder disease, hypertension, ischemic heart disease, known thrombogenic mutations, hepatocellular adenoma, malignant hepatoma, multiple risk factors for atherosclerotic cardiovascular disease, multiple sclerosis with prolonged immobility, history of peripartum cardiomyopathy, cigarette smoking and =35yo, history of complicated solid organ transplant, history of stroke, history of superficial venous thrombosis not associated with catheter, systemic lupus erythematosus with positive antiphospholipid antibodies, valvular heart disease complicated by pulmonary hypertension or atrial fibrillation or bacterial endocarditis, and acute viral hepatitis |
Country | Name | City | State |
---|---|---|---|
United States | Keck Medicine of USC--Downtown LA | Los Angeles | California |
United States | LAC+USC Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of ovulation suppression or dysfunction in relation to follicle size | Describe the ability of the contraceptive vaginal ring to cause ovulation suppression or dysfunction when placed in the mid and advanced follicular phase. This will be determined via measurement of steroid hormones and assessment of the leading ovarian follicle for signs of rupture after placement of the contraceptive vaginal ring. | The outcome is measured throughout the 6 week study. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00271583 -
Efficacy Trial of CDB 2914 for Emergency Contraception
|
Phase 2/Phase 3 | |
Completed |
NCT00777556 -
Emergency Contraception Actual Use Study
|
Phase 3 | |
Completed |
NCT00677755 -
Medical Abortion for Emergency Contraception Failure
|
N/A | |
Recruiting |
NCT06162611 -
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
|
Phase 4 | |
Completed |
NCT00411684 -
Safety and Efficacy of CDB-2914 for Emergency Contraception
|
Phase 3 | |
Completed |
NCT01569737 -
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
|
||
Completed |
NCT03208985 -
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
|
Phase 3 | |
Completed |
NCT02078414 -
Continued Use of Effective Contraception After Use of Emergency Contraception
|
||
Completed |
NCT01569113 -
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
|
Phase 4 | |
Completed |
NCT01963962 -
Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception
|
N/A | |
Active, not recruiting |
NCT02076217 -
Quick Start of Highly Effective Contraception
|
||
Not yet recruiting |
NCT04172584 -
Awareness & Use of Emergency Contraception
|
||
Completed |
NCT03395756 -
Depot Medroxyprogesterone Acetate as Emergency Contraception
|
Early Phase 1 | |
Completed |
NCT03614494 -
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception
|
Phase 2/Phase 3 |